Amal M. Johnson - Aug 11, 2021 Form 4 Insider Report for INTUITIVE SURGICAL INC (ISRG)

Role
Director
Signature
By: Donna Spinola For: Amal M. Johnson
Stock symbol
ISRG
Transactions as of
Aug 11, 2021
Transactions value $
-$2,021,387
Form type
4
Date filed
8/12/2021, 04:25 PM
Previous filing
Jul 30, 2021
Next filing
Nov 12, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISRG Common Stock Options Exercise $483K +2.5K +67.15% $193.08 6.22K Aug 11, 2021 Direct F1
transaction ISRG Common Stock Sale -$2.5M -2.5K -40.17% $1,001.63 3.72K Aug 11, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISRG Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.5K -50% $0.00 2.5K Aug 11, 2021 Common Stock 2.5K $193.08 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on December 15, 2021.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $998.78 to $1,006.18 as follows: 901 shares sold at $998.78 to $999.51; 600 shares sold at $1,000.229 to $1,001.23; 400 shares sold at $1,001.43 to $1,002.46; 599 shares sold at $1,005.22 to $1,006.18. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.